Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
S Afr Med J. 2021 Apr 15;111(6):575-581.
Empirical broad-spectrum antibiotics are frequently prescribed to patients with severe COVID-19, motivated by concern about bacterial coinfection. There is no evidence of benefit from such a strategy, while the dangers of inappropriate antibiotics are well described.
To investigate the frequency, profile and related outcomes of infections by bacterial pathogens in patients admitted to an intensive care unit (ICU) with severe COVID-19 pneumonia.
This was a prospective, descriptive study in a dedicated COVID-19 ICU in Cape Town, South Africa, involving all adult patients admitted to the ICU with confirmed COVID-19 pneumonia between 26 March and 31 August 2020. We collected data on patient comorbidities, laboratory results, antibiotic treatment, duration of admission and in-hospital outcome.
We included 363 patients, who collectively had 1 199 blood cultures, 308 tracheal aspirates and 317 urine cultures performed. We found positive cultures for pathogens in 20 patients (5.5%) within the first 48 hours of ICU admission, while 73 additional patients (20.1%) had positive cultures later during their stay. The most frequently isolated pathogens at all sites were Acinetobacter baumannii (n=54), Klebsiella species (n=13) and coagulase-negative staphylococci (n=9). Length of ICU stay (p<0.001) and intubation (p<0.001) were associated with positive cultures on multivariate analysis. Disease severity (p=0.5), early antibiotic use (p=0.5), diabetes mellitus (p=0.1) and HIV (p=0.9) were not associated with positive cultures. Positive cultures, particularly for tracheal aspirates (p<0.05), were associated with longer ICU length of stay and mortality. Early empirical antibiotic use was not associated with mortality (odds ratio 2.5; 95% confidence interval 0.95 - 6.81).
Bacterial coinfection was uncommon in patients at the time of admission to the ICU with severe COVID-19. Avoiding early empirical antibiotic therapy is therefore reasonable. Strategies to avoid coinfection and outbreaks in hospital, such as infection prevention and control, as well as the strict use of personal protective equipment, are important to improve outcomes.
由于担心细菌合并感染,临床医生经常给重症 COVID-19 患者开经验性广谱抗生素。但这种策略并没有益处,而且不恰当使用抗生素的危害众所周知。
调查入住南非开普敦一家专门收治 COVID-19 的 ICU 病房、患有重症 COVID-19 肺炎的患者中,细菌病原体感染的发生频率、特征及相关结局。
这是一项在南非开普敦一家专门收治 COVID-19 的 ICU 病房开展的前瞻性、描述性研究,纳入 2020 年 3 月 26 日至 8 月 31 日期间所有因确诊 COVID-19 肺炎而入住 ICU 的成年患者。我们收集了患者合并症、实验室结果、抗生素治疗、住院时间和院内结局等数据。
共纳入 363 例患者,他们的血液培养共 1199 次,气管抽吸物培养 308 次,尿液培养 317 次。在 ICU 入住的前 48 小时内,有 20 例(5.5%)患者的培养结果为阳性,而在住院期间的其余时间,有 73 例(20.1%)患者的培养结果为阳性。所有部位最常分离到的病原体均为鲍曼不动杆菌(n=54)、肺炎克雷伯菌(n=13)和凝固酶阴性葡萄球菌(n=9)。多变量分析显示,ICU 住院时间延长(p<0.001)和插管(p<0.001)与培养阳性相关。疾病严重程度(p=0.5)、早期抗生素使用(p=0.5)、糖尿病(p=0.1)和 HIV(p=0.9)与培养阳性均无关。培养阳性,特别是气管抽吸物培养阳性(p<0.05)与 ICU 住院时间延长和死亡率升高相关。早期经验性抗生素使用与死亡率无关(比值比 2.5;95%置信区间 0.95-6.81)。
入住 ICU 时重症 COVID-19 患者中细菌合并感染并不常见。因此,避免早期经验性抗生素治疗是合理的。为了改善结局,医院需要采取感染预防与控制等避免合并感染和暴发的策略,并严格使用个人防护设备。